2026-05-21T23:19:49Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/173742024-09-28T01:41:41Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19616

00925njm 22002777a 4500 dc Hortelano, Sonsoles author González-Cofrade, Laura author Cuadrado, Irene author de Las Heras, Beatriz author 2020-02 Increasing evidence supports NLRP3 inflammasome as a new target to control inflammation. Dysregulation of NLRP3 inflammasome has been reported to be involved in the pathogenesis of several human inflammatory diseases. However, no NLRP3 inflammasome inhibitors are available in clinic. Terpenoids are natural products with multi-target activities against inflammation. Recent studies have revealed that these compounds are capable of inhibiting the activation of NLRP3 inflammasome in several mouse models of NLRP3 inflammasome-related pathogenesis. Thus, terpenoids represent an interesting pharmacological approach for the treatment of inflammatory diseases as they are endowed with a dual mechanism of inhibition of NF-KB transcription factor and inflammasome activation, both critically involved in their anti-inflammatory effects. This work provides an overview of the current knowledge on the therapeutic potential of terpenoids as NLRP3 inflammasome inhibitors. Biochem Pharmacol. 2020 Feb:172:113739. 10.1016/j.bcp.2019.113739 1873-2968 Biochemical pharmacology 31786260 http://hdl.handle.net/20.500.12105/17374 Inflammation NLRP3-inflammasome Terpenoids Current status of terpenoids as inflammasome inhibitors